Hanmi

HANMI INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Hanmi Financial Corporation - HAFC

Retrieved on: 
Saturday, September 24, 2022

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (KSF), announces that KSF has commenced an investigation into Hanmi Financial Corporation (NasdaqGS: HAFC).

Key Points: 
  • Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (KSF), announces that KSF has commenced an investigation into Hanmi Financial Corporation (NasdaqGS: HAFC).
  • Recently, the court presiding over that case denied the Companys motion to dismiss, allowing the case to move forward.
  • KSFs investigation is focusing on whether Hanmis officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.
  • About Kahn Swick & Foti, LLC
    KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nations premier boutique securities litigation law firms.

Spectrum Pharmaceuticals Provides Update on Poziotinib Following FDA Oncologic Drugs Advisory Committee Meeting

Retrieved on: 
Thursday, September 22, 2022

The committee makes appropriate recommendations to the FDA, but these recommendations are not binding and the final decision regarding product approval will be made solely by the FDA.

Key Points: 
  • The committee makes appropriate recommendations to the FDA, but these recommendations are not binding and the final decision regarding product approval will be made solely by the FDA.
  • Spectrum Pharmaceuticals holds an exclusive license from Hanmi Pharmaceutical (Hamni) to develop, manufacture, and commercialize poziotinib worldwide, excluding Korea and China.
  • SPECTRUM PHARMACEUTICALS, INC. is a registered trademark of Spectrum Pharmaceuticals, Inc and its affiliate.
  • REDEFINING CANCER CARE and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

HANMI INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Hanmi Financial Corporation - HAFC

Retrieved on: 
Saturday, September 10, 2022

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (KSF), announces that KSF has commenced an investigation into Hanmi Financial Corporation (NasdaqGS: HAFC).

Key Points: 
  • Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (KSF), announces that KSF has commenced an investigation into Hanmi Financial Corporation (NasdaqGS: HAFC).
  • Recently, the court presiding over that case denied the Companys motion to dismiss, allowing the case to move forward.
  • KSFs investigation is focusing on whether Hanmis officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.
  • About Kahn Swick & Foti, LLC
    KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nations premier boutique securities litigation law firms.

Hanmi Financial (HAFC) Alert: Shareholder Class Action Survives Motion to Dismiss; Should Management be Held Accountable for Shareholder Losses? Contact Johnson Fistel

Retrieved on: 
Friday, August 19, 2022

You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing.

Key Points: 
  • You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing.
  • If you are interested in learning more about the investigation, please contact lead analyst Jim Baker ( [email protected] ) at 619-814-4471.
  • Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia.
  • The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits.

KT Corporation and Hanmi Pharmaceutical promote business cooperation with Digital Pharm, a Korean company specializing in digital treatment devices and electronic drugs

Retrieved on: 
Tuesday, June 21, 2022

KT and Hanmi Pharmaceutical to jointly invest in Digital Pharm, a company specializing in digital treatment devices and electronic drugs

Key Points: 
  • KT and Hanmi Pharmaceutical to jointly invest in Digital Pharm, a company specializing in digital treatment devices and electronic drugs
    SEOUL, South Korea, June 20, 2022 (GLOBE NEWSWIRE) -- Digital platform company KT Corporation (CEO Koo Hyun-mo; www.kt.com) and Hanmi Pharmaceutical (CEO Woo Jong-su, Kwon Se-chang), a pharmaceutical company specializing in R&D-focused new drug development, have co-invested in Digital Pharm, a company specializing in DTx and electroceuticals.
  • The companies announced on June 19, 2022 that KT and Hanmi completed their investments in Digital Pharm and held a launch ceremony.
  • In the future, KT plans to develop a digital treatment platform, establish business strategies for the new company, and build a pipeline of digital treatment devices and electroceuticals.
  • Hanmi will establish digital therapeutics B2H (business to hospital) and sales and marketing strategies to activate the nascent digital therapeutics prescription market.

Spectrum Pharmaceuticals to Present Data at 2022 ASCO Highlighting the Potential Predictive Capabilities of ctDNA as a Biomarker for Poziotinib Treatment Response

Retrieved on: 
Thursday, May 26, 2022

This early data suggests that a reduction in ctDNA may be a predictor of response to treatment with poziotinib, said Francois Lebel, M.D., Chief Medical Officer of Spectrum Pharmaceuticals.

Key Points: 
  • This early data suggests that a reduction in ctDNA may be a predictor of response to treatment with poziotinib, said Francois Lebel, M.D., Chief Medical Officer of Spectrum Pharmaceuticals.
  • We are encouraged by these findings and look forward to further investigate ctDNA as a potential predictive biomarker of poziotinib treatment response.
  • SPECTRUM PHARMACEUTICALS, INC. is a registered trademark of Spectrum Pharmaceuticals, Inc and its affiliate.
  • REDEFINING CANCER CARE and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

Hanmi Releases 2022 Environmental, Social and Governance (ESG) Report

Retrieved on: 
Tuesday, April 19, 2022

LOS ANGELES, April 19, 2022 (GLOBE NEWSWIRE) -- Hanmi Financial Corporation (NASDAQ: HAFC or Hanmi), the parent company of Hanmi Bank (the Bank), released its 2022 Environmental, Social and Governance (ESG) Report on April 15, 2022.

Key Points: 
  • LOS ANGELES, April 19, 2022 (GLOBE NEWSWIRE) -- Hanmi Financial Corporation (NASDAQ: HAFC or Hanmi), the parent company of Hanmi Bank (the Bank), released its 2022 Environmental, Social and Governance (ESG) Report on April 15, 2022.
  • Our ESG Report reflects our continued desire to provide transparency into our efforts around environmental, social and governance issues.
  • Among the many areas this report covers, key highlights include:
    Over the past four years, Hanmi employees have spent almost 2,500 hours volunteering in the community.
  • In February 2022, Hanmi made a long-term commitment of $7.5 million to a Community Reinvestment Act fund, with an initial investment of $830,000.

GRM Information Management Transforms Hanmi Bank Loan Processes with Digital Document Management Solution

Retrieved on: 
Wednesday, April 13, 2022

JERSEY CITY, N.J,  April 13, 2022 /PRNewswire-PRWeb/ --GRM Information Management, a leader in enterprise content management, has recently implemented a new solution for Hanmi Bank to automate and optimize their loan document management processes. Hanmi Bank, which boasts thirty-five branches and eight loan production offices across the country, is already recognizing the efficiencies and cost savings enabled by the cloud-based Loan Document Lifecycle Management software.

Key Points: 
  • GRM Information Management, a leader in enterprise content management, has recently implemented a new solution for Hanmi Bank to automate and optimize their loan document management processes.
  • JERSEY CITY, N.J, April 13, 2022 /PRNewswire-PRWeb/ --GRM Information Management, a leader in enterprise content management, has recently implemented a new solution for Hanmi Bank to automate and optimize their loan document management processes .
  • Hanmi Bank, which boasts thirty-five branches and eight loan production offices across the country, is already recognizing the efficiencies and cost savings enabled by the cloud-based Loan Document Lifecycle Management software.
  • GRM Information Management is a leading provider of document storage services and information management systems.

DGAP-News: Marinomed Biotech AG signs new agreement for Carragelose in South Korea

Retrieved on: 
Tuesday, April 12, 2022

Under the agreement, Hanmi is responsible for pursuing local approval for the Carragelose nasal spray and will market and distribute the product in South Korea.

Key Points: 
  • Under the agreement, Hanmi is responsible for pursuing local approval for the Carragelose nasal spray and will market and distribute the product in South Korea.
  • "We are delighted to enter into another licence agreement with a strong partner for the marketing of our Carragelose nasal spray in South Korea.
  • Marinomed Biotech AG is an Austrian science-based biotech company with globally marketed therapeutics.
  • Marinomed, Marinosolv(R) and Carragelose(R) are registered trademarks of Marinomed Biotech AG.

Spectrum Pharmaceuticals Appoints Juhyun Lim of Hanmi Pharmaceutical to Board of Directors

Retrieved on: 
Thursday, March 10, 2022

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Juhyun Lim to its Board of Directors.

Key Points: 
  • Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Juhyun Lim to its Board of Directors.
  • We are delighted to have Ms. Lim join Spectrums Board of Directors, said William Ashton, Chairman of the Board, Spectrum Pharmaceuticals.
  • SPECTRUM PHARMACEUTICALS, INC. and ROLONTIS are registered trademarks of Spectrum Pharmaceuticals, Inc and its affiliate.
  • REDEFINING CANCER CARE and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.